AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26491815 — intervention group
Group type: COMPARATOR
Intervention: Community health worker intervention during the first year after DCAS (control group intervention)
Number of subjects: 268
Study 26491815 — intervention group
Group type: COMPARATOR
Intervention: Usual care during DCAS (control group)
Number of subjects: 268
Study 26491815 — intervention group
Group type: COMPARATOR
Intervention: Community health worker intervention during the control group's intervention
Number of subjects: 268
Study 26491815 — intervention group
Group type: COMPARATOR
Intervention: Year after the control group's intervention
Number of subjects: 268
Study 24189215 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher values of tau (τ) indicating slowed V.O2 kinetics
Number of subjects: 85
Study 21244275 — intervention group
Group type: EXPERIMENTAL
Intervention: FD-APAP (2 × 500 mg tablets)
Number of subjects: 64
Study 21244275 — intervention group
Group type: COMPARATOR
Intervention: Standard acetaminophen (2 × 500 mg tablets)
Number of subjects: 64
Study 19841453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 microg twice daily for 6 months
Number of subjects: 114
Study 19841453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate, 500 microg twice daily for 30 months
Number of subjects: 114
Study 19841453 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone, 500 microg twice daily, and salmeterol, 50 microg twice daily for 30 months
Number of subjects: 114
Study 19841453 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 114
Study 17558758 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine-based anti-cellulite gel and LED treatments
Number of subjects: 9
Study 17558758 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel and LED treatments
Number of subjects: 9
Study 15198839 — intervention group
Group type: EXPERIMENTAL
Intervention: Kenalog (triamcinolone acetonide) spray
Number of subjects: 66
Study 15198839 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortizone‐10 Quick Shot (hydrocortisone) spray
Number of subjects: 66
Study 15198839 — intervention group
Group type: COMPARATOR
Intervention: Control (no corticosteroid spray)
Number of subjects: 66
Study 11403522 — intervention group
Group type: EXPERIMENTAL
Intervention: Two 15-minute naps per day
Number of subjects: 29
Study 11403522 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular schedule for nocturnal sleep
Number of subjects: 29
Study 11403522 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of scheduled naps and regular bedtimes
Number of subjects: 29
Study 11403522 — intervention group
Group type: COMPARATOR
Intervention: Control group (stimulant medications alone)
Number of subjects: 29
Study 9119854 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tourniquet release before closing the quadriceps layer (group B)
Number of subjects: 88
Study 9119854 — intervention group
Group type: COMPARATOR
Intervention: Standard tourniquet release after wound closure and bandaging (group A)
Number of subjects: 88
Study 8458044 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg twice a day
Number of subjects: 118
Study 8458044 — intervention group
Group type: COMPARATOR
Intervention: Piroxicam 20 mg once a day
Number of subjects: 118
Study 3023274 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective beta-blockade (BB, 80 mg propranolol)
Number of subjects: 6
Study 3023274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30686697 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer lactate (RL) for resuscitation and Dextrose Normal Saline (DNS) as maintenance in 1st 72h of burns (Group A)
Number of subjects: 200
Study 30686697 — intervention group
Group type: COMPARATOR
Intervention: Ringer lactate (RL) only for 1st 72h (Group B)
Number of subjects: 200
Study 28057081 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV)
Number of subjects: 135
Study 28057081 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin 20 mg (RSV)
Number of subjects: 135
Study 28057081 — intervention group
Group type: COMPARATOR
Intervention: Fimasartan 120 mg (FMS)
Number of subjects: 135
Study 25950687 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood stool test (BST) compliance
Number of subjects: 666
Study 25950687 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy use
Number of subjects: 666
Study 25950687 — intervention group
Group type: COMPARATOR
Intervention: Colonoscopy use among Haitian households
Number of subjects: 666
Study 24135513 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW)
Number of subjects: 292
Study 24135513 — intervention group
Group type: COMPARATOR
Intervention: Self-help condition
Number of subjects: 292
Study 24135513 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Watchers program (WW) with high usage of all 3 access modes
Number of subjects: 292
Study 21882156 — intervention group
Group type: EXPERIMENTAL
Intervention: Social reward
Number of subjects: 17
Study 21882156 — intervention group
Group type: EXPERIMENTAL
Intervention: Monetary reward
Number of subjects: 17
Study 21882156 — intervention group
Group type: COMPARATOR
Intervention: Control group response strategy
Number of subjects: 17
Study 19697997 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangosteen dietary supplement
Number of subjects: 59
Study 19697997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 16705479 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session Information Support Group Intervention
Number of subjects: 299
Study 16705479 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session Coping Improvement Group Intervention
Number of subjects: 299
Study 16705479 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Condition
Number of subjects: 299
Study 15325833 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 2838
Study 15325833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2838
Study 11314678 — intervention group
Group type: COMPARATOR
Intervention: MDMA (oral doses ranging from 70-150 mg, 1.35-1.8 mg/kg)
Number of subjects: 74
Study 9398711 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine (0.2 mg/day)
Number of subjects: 62
Study 9398711 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 8492053 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Integration Treatment (SIT)
Number of subjects: 96
Study 3812837 — intervention group
Group type: EXPERIMENTAL
Intervention: Chart reminders
Number of subjects: 162
Study 3812837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 162
Study 3812837 — intervention group
Group type: EXPERIMENTAL
Intervention: Both chart reminders and nicotine gum
Number of subjects: 162
Study 3812837 — intervention group
Group type: COMPARATOR
Intervention: Advice-only group (control)
Number of subjects: 162
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketanserin 20mg (n = 14)
Number of subjects: 26
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketanserin 40mg (n = 8)
Number of subjects: 26
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin 5mg (n = 4)
Number of subjects: 26
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserinol production
Number of subjects: 26
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak concentration of ketanserin
Number of subjects: 26
Study 2379381 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume of distribution
Number of subjects: 26
Study 4809462 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 (2 chloroethyl) 3 (4 methylcyclohexyl) 1 nitrosourea (methyl CCNU) at a dosage of 225 mg/sq m p.o. on day 1
Number of subjects: 43
Study 4809462 — intervention group
Group type: COMPARATOR
Intervention: Combination program utilizing 5 fluorouracil, cyclophosphamide, and prednisone with or without vincristine
Number of subjects: 43
Study 4809462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross over to methyl CCNU after initial treatment failure
Number of subjects: 43
Study 4809462 — intervention group
Group type: COMPARATOR
Intervention: Cross over to the combination program after initial treatment failure
Number of subjects: 43
Study 4809462 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyl CCNU
Number of subjects: 43
Study 4809462 — intervention group
Group type: COMPARATOR
Intervention: Combination programs
Number of subjects: 43
Study 4809462 — intervention group
Group type: COMPARATOR
Intervention: Vincristine (part of the combination program)
Number of subjects: 43
Study 31712893 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingxi black strain
Number of subjects: 0
Study 31712893 — intervention group
Group type: COMPARATOR
Intervention: Japanese strain
Number of subjects: 0
Study 27723955 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt room with halogenerator (treatment group)
Number of subjects: 55
Study 27723955 — intervention group
Group type: COMPARATOR
Intervention: Salt room without halogenerator (control group)
Number of subjects: 55
Study 26753646 — intervention group
Group type: EXPERIMENTAL
Intervention: New-pattern obstetrical nursing measures during pregnancy and puerperal period
Number of subjects: 680
Study 26753646 — intervention group
Group type: COMPARATOR
Intervention: Traditional nursing measures
Number of subjects: 680
Study 23408579 — intervention group
Group type: EXPERIMENTAL
Intervention: Face‐to‐face (FTF) clinic
Number of subjects: 295
Study 23408579 — intervention group
Group type: COMPARATOR
Intervention: Group conference calls (phone)
Number of subjects: 295
Study 21575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 962
Study 21575976 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 962
Study 21575976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 962
Study 19192459 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination lithium carbonate/nortriptyline
Number of subjects: 73
Study 19192459 — intervention group
Group type: COMPARATOR
Intervention: Continuation ECT
Number of subjects: 73
Study 19192459 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable (first week after remission)
Number of subjects: 73
Study 16790661 — intervention group
Group type: COMPARATOR
Intervention: Subgluteal approach
Number of subjects: 56
Study 16790661 — intervention group
Group type: COMPARATOR
Intervention: Posterior popliteal approach
Number of subjects: 56
Study 15066200 — intervention group
Group type: COMPARATOR
Intervention: Outreach intervention by a pharmacist with two visits, providing evidence summary and audit information over a seven-month period.
Number of subjects: 897
Study 11069320 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (after 4 days of placebo)
Number of subjects: 301
Study 11069320 — intervention group
Group type: COMPARATOR
Intervention: Placebo (first 4 days)
Number of subjects: 301
Study 9568319 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn blister fluid after thermal injury
Number of subjects: 11
Study 8095573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular artemether
Number of subjects: 65
Study 8095573 — intervention group
Group type: COMPARATOR
Intervention: Intravenous quinine
Number of subjects: 65
Study 3781336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 3781336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31663368 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ART initiators (CD4 >500 cells/mm3)
Number of subjects: 390
Study 31663368 — intervention group
Group type: COMPARATOR
Intervention: Late ART initiators (CD4 <200 cells/mm3)
Number of subjects: 390
Study 30032945 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx200 quality improvement intervention
Number of subjects: 121
Study 27544129 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with any SPARC expression (n=35)
Number of subjects: 50
Study 27544129 — intervention group
Group type: COMPARATOR
Intervention: Patients without SPARC expression (n=15)
Number of subjects: 50
Study 25400507 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 626
Study 25400507 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 626
Study 23739633 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow oxygen (HFO)
Number of subjects: 30
Study 23739633 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure (BiPAP)
Number of subjects: 30
Study 20508529 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephone intervention
Number of subjects: 5905
Study 20508529 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 5905
Study 18455084 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/d
Number of subjects: 0
Study 18455084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16649891 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial shock-wave therapy (RSWT)
Number of subjects: 90
Study 16649891 — intervention group
Group type: COMPARATOR
Intervention: Less active similar therapy (Control)
Number of subjects: 90
Study 12468784 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct percutaneous transluminal angioplasty (PTA)
Number of subjects: 70
Study 12468784 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis alone
Number of subjects: 70
Study 9486920 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chlorodeoxyadenosine (2-CdA)
Number of subjects: 19
Study 9486920 — intervention group
Group type: COMPARATOR
Intervention: 2-Chlorodeoxyadenosine (2-CdA) + daunorubicin (DNR)
Number of subjects: 19
Study 7619662 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.15, 0.3 and 0.6 micrograms kg‐1 i.v.)
Number of subjects: 0
Study 7619662 — intervention group
Group type: EXPERIMENTAL
Intervention: L-365,260 (10 mg, 50 mg p.o.)
Number of subjects: 0
Study 7619662 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin (0.3 micrograms kg‐1 i.v.)
Number of subjects: 0
Study 2793453 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (20 mg every 8 hours)
Number of subjects: 0
Study 2793453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions
Number of subjects: 0
Study 888714 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 0
Study 888714 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 31860521 — intervention group
Group type: EXPERIMENTAL
Intervention: Foveal sparing ILM peeling
Number of subjects: 34
Study 31860521 — intervention group
Group type: COMPARATOR
Intervention: Standard ILM peeling (control group)
Number of subjects: 34
Study 31102318 — intervention group
Group type: EXPERIMENTAL
Intervention: Low WWC1 expression
Number of subjects: 470
Study 31102318 — intervention group
Group type: COMPARATOR
Intervention: High WWC1 expression
Number of subjects: 470
Study 29853785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 60
Study 29853785 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 60
Study 26894822 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 12
Study 26894822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25447269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% (once daily)
Number of subjects: 564
Study 25447269 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% (twice daily)
Number of subjects: 564
Study 25447269 — intervention group
Group type: COMPARATOR
Intervention: Tafluprost 0.0015% (once daily)
Number of subjects: 564
Study 25447269 — intervention group
Group type: EXPERIMENTAL
Intervention: Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5%
Number of subjects: 564
Study 25447269 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5%
Number of subjects: 564
Study 22114059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT) applied once a week (G1)
Number of subjects: 50
Study 22114059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Therapy (CT) applied twice a week (G2)
Number of subjects: 50
Study 19922664 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected adults
Number of subjects: 339
Study 19922664 — intervention group
Group type: COMPARATOR
Intervention: HIV-1 uninfected adults
Number of subjects: 339
Study 19922664 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1 infected and uninfected adults
Number of subjects: 339
Study 17980977 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg sodium nitrate for 28 days
Number of subjects: 20
Study 17980977 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (control)
Number of subjects: 20
Study 16354890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptives
Number of subjects: 162
Study 16354890 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestin‐only pill
Number of subjects: 162
Study 16354890 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper intrauterine device (IUD)
Number of subjects: 162
Study 16354890 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 162
Study 11942868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 2 mg/kg
Number of subjects: 120
Study 11942868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketoprofen 2 mg/kg
Number of subjects: 120
Study 11942868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscular)
Number of subjects: 120
Study 11942868 — intervention group
Group type: COMPARATOR
Intervention: Placebo (both intravenous and intramuscular)
Number of subjects: 120
Study 11942868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 120
Study 11942868 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ketoprofen
Number of subjects: 120
Study 9794747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide daily
Number of subjects: 93
Study 9794747 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bendrofluazide daily
Number of subjects: 93
Study 9794747 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide every other day
Number of subjects: 93
Study 9794747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study 15374200 — intervention group
Group type: EXPERIMENTAL
Intervention: standardised ginseng‐containing vitamin complex
Number of subjects: 60
Study 15374200 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study 2633288 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Number of subjects: 100
Study 2633288 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 100
Study 876437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of amoxycillin (3 g for adults and 100 mg/kg for children)
Number of subjects: 31
Study 876437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of amoxycillin
Number of subjects: 31
Study 876437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose therapy
Number of subjects: 31
Study 31441437 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium chain triglyceride‐Olive‐Fish‐Soy lipid emulsion (MOFS‐LE)
Number of subjects: 40
Study 31441437 — intervention group
Group type: COMPARATOR
Intervention: Soybean oil‐based lipid emulsion (S‐LE)
Number of subjects: 40
Study 27782976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP) using oral magnesium citrate
Number of subjects: 148
Study 27782976 — intervention group
Group type: COMPARATOR
Intervention: Sodium phosphate (NaP) enema alone
Number of subjects: 148
Study 27782976 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 148
Study 27782976 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 148
Study 25565485 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g of fish oil (240 mg EPA + 240 mg DHA) with a multivitamin
Number of subjects: 160
Study 25565485 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of fish oil (480 mg EPA + 480 mg DHA) with a multivitamin
Number of subjects: 160
Study 25565485 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of fish oil without a multivitamin
Number of subjects: 160
Study 25565485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 23831445 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded covered stents (Viabahn)
Number of subjects: 141
Study 23831445 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 141
Study 21411235 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment for comorbid SUD and PTSD
Number of subjects: 102
Study 19286192 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract EGb 761 (240 mg/day)
Number of subjects: 395
Study 19286192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 395
Study 17553671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA)
Number of subjects: 225
Study 17553671 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 225
Study 17553671 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate (VPA) and Lamotrigine (LTG)
Number of subjects: 225
Study 15334286 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microgrammes recombinant hepatitis B vaccine
Number of subjects: 92
Study 15334286 — intervention group
Group type: COMPARATOR
Intervention: 20 microgrammes recombinant hepatitis B vaccine
Number of subjects: 92
Study 15334286 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 92
Study 11486448 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B
Number of subjects: 0
Study 11486448 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 0
Study 9710861 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO2
Number of subjects: 161
Study 9710861 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal cut point of 18.3 mL.kg-1.min-1
Number of subjects: 161